Biosyngen to set up China-Singapore Translational Medicine Centre

12 July 2023 | News

For linking talent and resources in Singapore and the Greater Bay Area (China) in pursuit of clinical outcomes benefitting patients

Image caption- KCI Group Deputy Party Secretary, Lily Peng, (Right) Minister-of-state, Alvin Tan

The 13^th Singapore Guangdong Collaboration Council was recently held in Singapore, where leaders from both governments (China & Singapore) witnessed the signing of 12 collaboration agreements.

Totalling 3 billion RMB, these agreements represent deeper partnership between the two countries, adding momentum to the wider Singapore-China collaboration blueprint. Among the agreements, the only collaboration in the biomedical domain is by Biosyngen to set up the China-Singapore Technology Innovation and Translational Medicine Centre for Tumour Prevention and Treatment.

Through the Guangzhou Development District, this Translational Medicine Centre is jointly established by the Guangzhou Knowledge City Investment Group (KCI Group) and Biosyngen, which opens the doors to technology from overseas. With this Translational Medicine Centre, Biosyngen and KCI Group will deepen R&D and improve clinical development.

Since establishing the company in 2016, Biosyngen has taken a global focus. With a dual headquarter in Singapore and Guangzhou, with R&D talent from 6 countries; the company has 2 first-in-class products granted investigational new drug (IND) by US and China. In addition, there are 3 other first-in-class products planned for IND submissions.